Research is an important part of what we do at West London NHS Trust. We’re currently involved in over 20 studies across different areas of mental and physical health.
We are currently working on numerous research projects across Covid-19, dementia and mental health.
The National Institute of Health Research (NIHR) is leading on strategy for researching Covid-19 and will be identifying new studies. Where possible, the Trust will endeavour to support research in this area as directed.
We actively encourage our staff and service users to become involved in research.
You can find out more about just some of our active research studies below.
Covid-19 Social Study – UK
This study aims to identify how the news about coronavirus is affecting people, whether people are having to isolate and their experiences of isolating.
It aims to inform understanding about the effects of social isolation measures on people’s mental health. The findings will be used to help develop ways to support people psychologically and socially during this outbreak.
Participation is open to people over the age of 18 living in the UK and is entirely voluntary. You don’t have to be isolating to take part.
You’ll be asked to complete one survey now and then a shorter one once a week while this pandemic continues and social isolation measures are in place. You can opt out of taking part in future surveys at any point by simply ignoring the follow-up invitation.
NorAD clinical trial
Currently approved drugs for Alzheimer’s Disease (the most common cause of dementia), have a very small effect on thinking and quality of life. This trial looks at whether boosting noradrenaline, in addition to standard treatment, will improve attention and more general aspects of thinking in patients with Alzheimer’s Disease.
This is a randomised controlled trial which means that half the participants will receive a drug called Guanfacine, which has been shown to boost attention and memory in animal studies and in healthy humans, and is licensed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The other half will be given a placebo (a drug which has no effect on the person taking it).
This will help assess whether Guanfacine, in addition to standard treatment, will improve attention and more general aspects of thinking in patients with Alzheimer’s Disease.
Sleep and psychotic features: this study is currently on hold due to Covid-19.
People who suffer from mental health disorders often have difficulties regulating their mood and emotions. They’re also often troubled with disrupted sleeping patterns which can range from being unable to fall asleep, sleeping at the wrong time of day or having excessive sleepiness.
Poor sleep also predicts a relapse or sudden worsening of symptoms. We’re interested in finding out whether there’s an association between the difficulty of regulating mood and of sleep patterns.
This study has been designed to investigate the relationship between sleep and mood in people who’ve been referred to NHS mental health services, to understand if sleep problems are present in these people.